請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42164
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 俞松良(Sung-Liang Yu) | |
dc.contributor.author | Yu-Shuang Lin | en |
dc.contributor.author | 林俞雙 | zh_TW |
dc.date.accessioned | 2021-06-15T00:50:16Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-15 | |
dc.identifier.citation | 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150. 3. Department of health ROC, Taiwan: Cancer register report. In.; 2007. 4. Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2002(155):1-781. 5. P SBK: World cancer report. Lyon: IARC Presse Med 2003. 6. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003, 124(2):544-560. 7. Ferretti S, Patriarca S, Carbone A, Zanetti R: TNM classification of malignant tumours, VII edition 2009. Changes and practical effects on cancer epidemiology. Epidemiol Prev 2010, 34(3):125-128. 8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66. 9. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306(6880):752-755. 10. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914. 11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30. 12. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007, 25(29):4557-4561. 13. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23(16):3706-3712. 14. Maiello E, Giuliani F, Gebbia V, Piano A, Agueli R, Colucci G: Cetuximab: clinical results in colorectal cancer. Ann Oncol 2007, 18 Suppl 6:vi8-10. 15. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR: Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007, 6(6):427-432. 16. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995, 19(1):59-71. 17. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77(11):1241-1246. 18. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 1994, 343(8910):1405-1410. 19. Eng C: Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009, 6(4):207-218. 20. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006, 127(4):679-695. 21. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12(8):895-904. 22. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115(1):44-55. 23. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524. 24. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549. 25. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW: Guidelines for resection of colorectal cancer liver metastases. Gut 2006, 55 Suppl 3:iii1-8. 26. Schlag PM, Benhidjeb T, Stroszczynski C: Resection and local therapy for liver metastases. Best Pract Res Clin Gastroenterol 2002, 16(2):299-317. 27. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM: Hepatic resection for colorectal metastases - Value for risk scoring systems? Annals of Surgery 2007, 246(2):183-191. 28. Bishop DT, Hall NR: The genetics of colorectal cancer. Eur J Cancer 1994, 30A(13):1946-1956. 29. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al: Identification of FAP locus genes from chromosome 5q21. Science 1991, 253(5020):661-665. 30. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M et al: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66(3):589-600. 31. Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B et al: Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993, 75(5):951-957. 32. Nagase H, Nakamura Y: Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993, 2(6):425-434. 33. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y: Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992, 1(4):229-233. 34. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 2001, 93(3):346-352. 35. Prasad K, Mantha SV, Kalra J, Lee P: Prevention of Hypercholesterolemic Atherosclerosis by Garlic, an Antixoidant. J Cardiovasc Pharmacol Ther 1997, 2(4):309-320. 36. Ammon HP, Wahl MA: Pharmacology of Curcuma longa. Planta Med 1991, 57(1):1-7. 37. Tonnesen HH, Karlsen J: Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 1985, 180(5):402-404. 38. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK: Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15(12):1867-1876. 39. Tonnesen HH, Karlsen J, van Henegouwen GB: Studies on curcumin and curcuminoids. VIII. Photochemical stability of curcumin. Z Lebensm Unters Forsch 1986, 183(2):116-122. 40. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R: Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995, 94(1):79-83. 41. Srimal RC, Dhawan BN: Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973, 25(6):447-452. 42. Kuttan R, Bhanumathy P, Nirmala K, George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 1985, 29(2):197-202. 43. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M, Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005, 223(2):181-190. 44. Dhir V, Mohandas KM: Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999, 18(1):24-28. 45. Mohandas KM, Nagral A: Epidemiology of digestive tract cancers in India. II. Stomach, and gastrointestinal lymphomas. Indian J Gastroenterol 1998, 17(1):24-27. 46. Dhir V, Mohandas KM: Epidemiology of digestive tract cancers in India. III. Liver. Indian J Gastroenterol 1998, 17(3):100-103. 47. Huang MT, Smart RC, Wong CQ, Conney AH: Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988, 48(21):5941-5946. 48. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM: Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000, 21(5):921-927. 49. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B):2895-2900. 50. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14(14):4491-4499. 51. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Jr. et al: Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011, 4(3):354-364. 52. Chen HW, Huang HC: Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998, 124(6):1029-1040. 53. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S: Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 2007, 102(3):580-592. 54. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I kappa B alpha kinase and Akt activation. Molecular Pharmacology 2006, 69(1):195-206. 55. Bharti AC, Donato N, Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171(7):3863-3871. 56. Park CH, Hahm ER, Park S, Kim HK, Yang CH: The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 2005, 579(13):2965-2971. 57. Menon LG, Kuttan R, Kuttan G: Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999, 141(1-2):159-165. 58. Menon LG, Kuttan R, Kuttan G: Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995, 95(1-2):221-225. 59. Herman JG, Stadelman HL, Roselli CE: Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol 2009, 34(5):1319-1327. 60. Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY: The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 2006, 9(2):147-152. 61. Sameermahmood Z, Balasubramanyam M, Saravanan T, Rema M: Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs). Invest Ophthalmol Vis Sci 2008, 49(8):3305-3311. 62. Huang MT, Newmark HL, Frenkel K: Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 1997, 27:26-34. 63. Tunstall RG, Sharma RA, Perkins S, Sale S, Singh R, Farmer PB, Steward WP, Gescher AJ: Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials. Eur J Cancer 2006, 42(3):415-421. 64. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM et al: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(20):6847-6854. 65. Chen H, Zhang ZS, Zhang YL, Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999, 19(5A):3675-3680. 66. Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM, Van Ommen B: Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog 2004, 3(1):8. 67. Nair J, Strand S, Frank N, Knauft J, Wesch H, Galle PR, Bartsch H: Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation. Carcinogenesis 2005, 26(7):1307-1315. 68. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Research 2002, 62(13):3868-3875. 69. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA: Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004, 25(9):1611-1617. 70. Frank N, Knauft J, Amelung F, Nair J, Wesch H, Bartsch H: No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 2003, 523:127-135. 71. Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, Su SF, Huang CW, Ho CC, Chen JJ, Tsai MF et al: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008, 68(18):7428-7438. 72. Sood PK, Nahar U, Nehru B: Curcumin Attenuates Aluminum-Induced Oxidative Stress and Mitochondrial Dysfunction in Rat Brain. Neurotox Res 2011, Epub. 73. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N: Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Research 2008, 68(8):2803-2812. 74. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N: CD24 is a new oncogene, early at the multistep process-of colorectal cancer carcinogenesis. Gastroenterology 2006, 131(2):630-639. 75. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Annals of Surgical Oncology 2007, 14:2748-2758. 76. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clinical Cancer Research 2005, 11(18):6574-6581. 77. Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY, Ahn G: Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecologic Oncology 2005, 97(2):379-386. 78. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61(10):4143-4154. 79. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10(12 Pt 1):4109-4117. 80. Serrels B, Serrels A, Brunton VG, Holt M, McLean GW, Gray CH, Jones GE, Frame MC: Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol 2007, 9(9):1046-1056. 81. Vial D, Oliver C, Jamur MC, Pastor MV, da Silva Trindade E, Berenstein E, Zhang J, Siraganian RP: Alterations in granule matrix and cell surface of focal adhesion kinase-deficient mast cells. J Immunol 2003, 171(11):6178-6186. 82. Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC, Shen TL: Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol 2010, 177(4):1629-1637. 83. Yom CK, Noh DY, Kim WH, Kim HS: Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat 2010, 128(3):647-655. 84. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH: Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol 2010, 41(12):1664-1673. 85. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006, 7(2):131-142. 86. Avizienyte E, Frame MC: Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Current Opinion in Cell Biology 2005, 17(5):542-547. 87. Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, Sheu HM, Shi GY, Wu HL: Downregulation of thrombomodulin, a novel target of Snail, induces tumorigenesis through epithelial-mesenchymal transition. Mol Cell Biol, 30(20):4767-4785. 88. Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C: New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 2008, 52(9):1040-1061. 89. Wang X, Wang Q, Ives KL, Evers BM: Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 2006, 12(18):5346-5355. 90. Su CC, Chen GW, Lin JG, Wu LT, Chung JG: Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006, 26(2A):1281-1288. 91. Lin SS, Lai KC, Hsu SC, Yang JS, Kuo CL, Lin JP, Ma YS, Wu CC, Chung JG: Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett 2009, 285(2):127-133. 92. Sandur SK, Deorukhkar A, Pandey MK, Pabon AM, Shentu S, Guha S, Aggarwal BB, Krishnan S: Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 2009, 75(2):534-542. 93. Kristiansen G, Sammar M, Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004, 35(3):255-262. 94. Su MC, Hsu C, Kao HL, Jeng YM: CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006, 235(1):34-39. 95. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I: CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003, 88(2):231-236. 96. Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M et al: CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci. 97. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K: CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998, 12(12):1241-1251. 98. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M et al: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997, 89(9):3385-3395. 99. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D: The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006, 66(4):1917-1922. 100. Shishodia S, Singh T, Chaturvedi MM: Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007, 595:127-148. 101. Kang Q, Chen A: Curcumin inhibits srebp-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 2009, 150(12):5384-5394. 102. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, 3rd, Li X, Safe S: Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008, 68(13):5345-5354. 103. Cui J, Meng X, Gao X, Tan G: Curcumin decreases the expression of Pokemon by suppressing the binding activity of the Sp1 protein in human lung cancer cells. Mol Biol Rep 2009, 37(3):1627-1632. 104. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D: Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1648-1652. 105. Safe S, Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 2005, 41(16):2438-2448. 106. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ: Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005, 65(3):1007-1017. 107. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 2004, 21(8):755-764. 108. Szalad A, Katakowski M, Zheng X, Jiang F, Chopp M: Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J Exp Clin Cancer Res 2009, 28:129. 109. Cho SG, Yi Z, Pang X, Yi T, Wang Y, Luo J, Wu Z, Li D, Liu M: Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 2009, 69(17):7062-7070. 110. Luo Y, Liang F, Zhang ZY: PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009, 48(8):1838-1846. 111. Takami Y, Russell MB, Gao C, Mi Z, Guo H, Mantyh CR, Kuo PC: Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery 2007, 142(2):163-169. 112. Ray S, Chattopadhyay N, Mitra A, Siddiqi M, Chatterjee A: Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol 2003, 22(1):49-58. 113. Banerji A, Chakrabarti J, Mitra A, Chatterjee A: Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004, 211(2):235-242. 114. Holy J: Curcumin inhibits cell motility and alters microfilament organization and function in prostate cancer cells. Cell Motil Cytoskeleton 2004, 58(4):253-268. 115. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2(5):249-256. 116. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004, 6(2):154-161. 117. Leu TH, Su SL, Chuang YC, Maa MC: Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol 2003, 66(12):2323-2331. 118. Lin HJ, Su CC, Lu HF, Yang JS, Hsu SC, Ip SW, Wu JJ, Li YC, Ho CC, Wu CC et al: Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2, -9, FAK, Rho A and Rock-1 gene expression. Oncol Rep 2010, 23(3):665-670. 119. Kim DK, Kim SJ, Kang SS, Jin EJ: Curcumin inhibits cellular condensation and alters microfilament organization during chondrogenic differentiation of limb bud mesenchymal cells. Exp Mol Med 2009, 41(9):656-664. 120. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377(6549):539-544. 121. Easley CAt, Brown CM, Horwitz AF, Tombes RM: CaMK-II promotes focal adhesion turnover and cell motility by inducing tyrosine dephosphorylation of FAK and paxillin. Cell Motil Cytoskeleton 2008, 65(8):662-674. 122. van Miltenburg MH, Lalai R, de Bont H, van Waaij E, Beggs H, Danen EH, van de Water B: Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility. FASEB J 2009, 23(10):3482-3493. 123. Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q: An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 2009, 76(6):1238-1245. 124. Ohashi Y, Tsuchiya Y, Koizumi K, Sakurai H, Saiki I: Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology 2003, 65(3):250-258. 125. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2(6):442-454. 126. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD: E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A 1999, 96(11):6249-6254. 127. Chao YL, Shepard CR, Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010, 9:179. 128. Vleminckx K, Vakaet L, Jr., Mareel M, Fiers W, van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66(1):107-119. 129. Wong TS, Chan WS, Li CH, Liu RW, Tang WW, Tsao SW, Tsang RK, Ho WK, Wei WI, Chan JY: Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin. Anticancer Res 2010, 30(7):2851-2856. 130. LI Yu YL-x, CHEN Zhao-qing,LI Jian,LI Ya-dong,NIU Jian-zhao Influence of curcumin on smad signal transduction pathway of EMT. Journal of Beijing University of Traditional Chinese Medicine 2009. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42164 | - |
dc.description.abstract | 在許多已開發國家,因為飲食習慣的改變,致使大腸直腸癌的發生率逐漸增加,成為人類死亡的主要威脅之一。臨床上對於大腸直腸癌的主要治療方式為:外科手術切除原位腫瘤或配合使用化學治療和放射治療來殺死轉移的癌細胞。然而,癌症的轉移仍是造成大腸直腸癌病人死亡的主要原因。薑黃素(curcumin)應用於人類的醫療已經有上千年的歷史,是一種非常重要的傳統藥物。一直以來,薑黃素被認為可以治療許多包含癌症在內的人類疾病。近年來有許多研究證實薑黃素能夠抑制腫瘤細胞的許多生理特性,但是其調控的機制尚不清楚。本研究主要探討薑黃素對抗大腸直腸癌轉移的機制。首先,我們發現在大腸直腸癌細胞株HCT-116中,給予次致死劑量的薑黃素(0-20 µM),可以有效抑制細胞的移動能力(於20 µM 有85.2%的抑制性)以及細胞的侵襲能力(於20 µM 有99%的抑制性),除此之外,我們也發現薑黃素可以有效抑制大腸直腸癌細胞轉移到肝臟的能力。接著,我們使用基因表現晶片探討會受薑黃素調控的基因。經由統計分析(p<0.05, FDR)發現,相對於控制組,共有1239個基因在有薑黃素(20μM)的情況下,其表現量會有兩倍以上的差異。利用MetaCore軟體進一步分析基因的傳導網絡,我們發現細胞貼附、細胞骨架重組以及Sp1轉錄因子的調控網路都可能參與調控薑黃素所引發的抗癌作用。進一步分子生物實驗結果顯示,細胞貼附及細胞骨架重組這兩個訊息傳導的關鍵分子-FAK蛋白會受到薑黃素的抑制。而Sp1轉錄因子的轉錄能力也會受到薑黃素的調控而下降,進而使下游的基因轉錄也受到抑制。由本研究的實驗結果發現,薑黃素對抗大腸直腸癌細胞轉移的能力可能是透過抑制FAK蛋白的訊息路徑和降低Sp1轉錄因子的轉錄能力。 | zh_TW |
dc.description.abstract | Colon cancer has become a serious threat to public health due to the changes of the dietary habits in many developed countries. In clinic, the standard therapeutic strategies for colon cancers are complete surgery resection for local diseases, and systematic chemotherapy and radiotherapy for metastatic diseases. However, tumor metastasis is the primary cause resulting in cancer death. Curcumin has been used as an important traditional medicine in almost any kind of illness including cancers. Over the past years, curcumin has been proved to be a multifunctional chemotherapeutic agent. However, the anti-tumor mechanism of curcumin is not completely understood yet. In this study, we investigate the underlying anti-metastasis mechanism of curcumin in colorectal cancer. Our results showed that sub-lethal dose (0-20 µM) of curcumin could inhibit cell migration (85.2% of inhibition at 20 µM) and cell invasion (99% of inhibition at 20 µM) in a dose-dependent manner in colon cancer cells. Additionally, curcumin inhibited liver metastasis of colorectal cancer in vivo. The differentially expressed genes of colon cancer cells treated with 20 µM curcumin were analyzed by Affymetrix genechip compared with mocks. There are 1,239 genes with greater than 2-fold change (p<0.05, FPR). The microarray analysis by using MetaCore software indicated that cell adhesion pathway, cytoskeleton remodeling pathway and Specificity protein-1(Sp1) transcriptional regulation may be involved in the anti-metastasis activity of curcumin. Our results showed that FAK signaling pathway which mediates cell adhesion and cytoskeleton remodeling was repressed by curcumin. Besides, the Sp1 transcriptional activity was found to be inhibited by curcumin. These findings suggest that curcumin might execute anti-metastasis activity by down-regulation of Sp1 transcriptional activity and suppression of FAK signaling. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T00:50:16Z (GMT). No. of bitstreams: 1 ntu-100-R98424012-1.pdf: 6494332 bytes, checksum: 985ef07f3b2e506300fefbd65b5a9797 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Contents
中文摘要 1 Abstract 2 Chapter 1. Introduction 4 1.1 Colorectal cancer 4 1.1.1 Population 5 1.1.2 Cancer staging 5 1.1.3 Management and prognosis 8 1.1.4 Cancer metastasis and clinical limit 9 1.1.5 Pathogenesis 10 1.2 Curcumin 10 1.2.1 Chemical properties and traditional uses 10 1.2.2 Anti-cancer potential of curcumin 12 1.2.3 Curcumin and cancer metastasis 13 1.2.4 Effect of curcumin on colorectal cancer 14 1.3 Specific aim 15 1.4 Experimental profile 16 Chapter 2. Materials and Methods 17 2.1 Reagent 18 2.2 Cell lines 18 2.3 Cell viability 18 2.4 Wound healing assay 19 2.5 Matrigel invasion assay 19 2.6 Transwell migration assay 20 2.7 Anchorage independent colony formation assay 20 2.8 In vivo experiment 21 2.9 RNA extraction 22 2.10 Microarray analysis 22 2.11 Real time quantitative PCR 23 2.12 Western blot analysis 24 2.13 Cell adhesion assay 25 2.14 Flow cytometry 26 2.15 Sp1 reporter construction and luciferase assay 26 Chapter 3. Results 28 3.1 Optimal dose of curcumin and candidate colon cancer cell line 29 3.2 Sub-lethal dose of curcumin suppresses the motility of colon cancer cells 30 3.3 Curcumin inhibits tumor growth and liver metastasis in vivo 32 3.4 Microarray analysis of curcumin-regulated gene expression in HCT-116 cells 33 3.5 CD24 is not a potential target in HCT-116 cell model 34 3.6 Curcumin suppresses Sp1 transcriptional activity and decreases downstream gene expression 35 3.7 Effect of curcumin on FAK regulated cytoskeleton remodeling and cell adhesion pathways 37 3.8 The potential inhibitory effect of curcumin on epithelial-mesenchymal transition 38 Chapter 4. Discussion 40 Chapter 5. Figures 49 Chapter 6. References 68 Chapter 7. Appendices 80 | |
dc.language.iso | en | |
dc.title | 薑黃素抑制大腸直腸癌細胞轉移之機轉 | zh_TW |
dc.title | Anti-metastasis Mechanism of Curcumin in Colorectal Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林淑萍(Shwu-Bin Lin),林亮音(Liang-In Lin),楊雅倩(Ya-Chien Yang) | |
dc.subject.keyword | 大腸直腸癌,薑黃素,癌轉移,微陣列分析,SP1轉錄因子,FAK, | zh_TW |
dc.subject.keyword | colorectal cancer,curcumin,cancer metastasis,microarray analysis,SP1 transcriptional factor,FAK, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 6.34 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。